Table 4 Absolute and average cumulative doses and cause-specific mortality.

From: Differential association between cumulative dose of 5α-reductase inhibitors and mortality

Variables

Control (n = 756)

Case (n = 154)

Completed Suicide

p-for-trend

n

(%)

n

(%)

aHRa

95% CI

5-alpha reductase inhibitor

         

Never user (less than 30 cDDDs)

370

(48.9)

57

(37.0)

1.000

    

Ever user

386

(51.1)

97

(63.0)

1.835

1.149

-

2.932

 

Cumulative dose

        

0.3051

Less than 365 cDDDs

132

(34.2)

39

(40.2)

2.025

1.130

-

3.628

365 ~ 730 cDDDs

49

(12.7)

15

(15.5)

1.807

0.815

-

4.006

730 ~ 1460 cDDDs

48

(12.4)

18

(18.6)

2.591

1.207

-

5.563

1460 ~ 2920 cDDDs

59

(15.3)

13

(13.4)

1.415

0.608

-

3.291

More than 2920 cDDDs

98

(25.4)

12

(12.4)

1.123

0.475

-

2.652

Average cumulative dose per year

         

Less than 30 cDDDs/year

68

(17.6)

26

(26.8)

2.004

1.000

-

4.018

0.2521

30 ~ 180 cDDDs/year

128

(33.2)

32

(33.0)

1.880

1.040

-

3.400

180 ~ 365 cDDDs/year

52

(13.5)

18

(18.6)

2.864

1.319

-

6.218

365 ~ 730 cDDDs/year

64

(16.6)

16

(16.5)

1.842

0.841

-

4.032

More than 730 cDDDs/year

74

(19.2)

5

(5.2)

0.620

0.202

-

1.903

Variables

Control (n = 1303)

Case (n = 271)

Due to CVD

p-for-trend

n

(%)

n

(%)

aHR

95% CI

5-alpha reductase inhibitor

         

Never user (less than 30 cDDDs)

589

(45.2)

113

(41.7)

1.000

    

Ever user

714

(54.8)

158

(58.3)

0.840

0.585

-

1.207

 

Cumulative dose

        

0.0533

Less than 365 cDDDs

233

(32.6)

57

(36.1)

0.914

0.575

-

1.452

365 ~ 730 cDDDs

90

(12.6)

27

(17.1)

1.373

0.713

-

2.644

730 ~ 1460 cDDDs

101

(14.1)

21

(13.3)

0.835

0.436

-

1.598

1460 ~ 2920 cDDDs

110

(15.4)

27

(17.1)

0.824

0.433

-

1.566

2920 ~ 5840 cDDDs

77

(10.8)

18

(11.4)

1.038

0.497

-

2.170

More than 5840 cDDDs

103

(14.4)

8

(5.1)

0.285

0.115

-

0.702

Average cumulative dose per year

         

Less than 30 cDDDs/year

128

(17.9)

30

(19.0)

0.837

0.465

-

1.507

0.0987

30 ~ 180 cDDDs/year

241

(33.8)

60

(38.0)

0.975

0.614

-

1.548

180 ~ 365 cDDDs/year

113

(15.8)

27

(17.1)

0.876

0.457

-

1.676

365 ~ 730 cDDDs/year

92

(12.9)

22

(13.9)

1.065

0.552

-

2.056

More than 730 cDDDs/year

140

(19.6)

19

(12.0)

0.423

0.213

-

0.840

Variables

Control (n = 1283)

Case (n = 267)

Due to other causesb

p-for-trend

n

(%)

n

(%)

aHR

95% CI

5-alpha reductase inhibitor

         

Never user (less than 30 cDDDs)

1819

(45.2)

321

(37.4)

1.000

    

Ever user

2202

(54.8)

537

(62.6)

1.279

1.048

-

1.562

 

Cumulative dose

        

0.5657

Less than 365 cDDDs

779

(35.4)

231

(43.0)

1.449

1.137

-

1.846

365 ~ 730 cDDDs

272

(12.4)

72

(13.4)

1.475

1.028

-

2.117

730 ~ 1460 cDDDs

319

(14.5)

79

(14.7)

1.314

0.918

-

1.883

1460 ~ 2920 cDDDs

293

(13.3)

66

(12.3)

1.145

0.788

-

1.664

2920 ~ 5840 cDDDs

250

(11.4)

47

(8.8)

0.764

0.498

-

1.170

More than 5840 cDDDs

292

(13.3)

42

(7.8)

0.978

0.635

-

1.504

Average cumulative dose per year

         

Less than 30 cDDDs/year

443

(20.1)

119

(22.2)

1.249

0.921

-

1.693

0.8621

30 ~ 180 cDDDs/year

741

(33.7)

214

(39.9)

1.542

1.203

-

1.976

180 ~ 365 cDDDs/year

333

(15.1)

76

(14.2)

1.350

0.942

-

1.936

365 ~ 730 cDDDs/year

263

(11.9)

64

(11.9)

1.046

0.714

-

1.534

730 ~ 1460 cDDDs/year

254

(11.5)

45

(8.4)

0.986

0.642

-

1.513

More than 1460 cDDDs/year

171

(7.8)

19

(3.5)

0.709

0.389

-

1.294

  1. The text in bold font indicates a statistically significant difference.
  2. Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; cDDD, cumulative defined daily dose; CVD, cardiovascular disease.
  3. a Adjusted for Area of residence, Economic status, Insurance type, Physical activity, Alcohol status, Smoking status, Body mass index, Number of outpatient visits per year, Number of admissions, Alpha blocker, Prostate surgical intervention, Comorbidity.
  4. b Including every cause except cardiovascular diseases such as stroke and acute myocardial infarction, completed suicides (intentional self-harm), physical trauma (e.g., car accidents, falls), chronic obstructive pulmonary disease, pneumonia, diabetes mellitus, infections, and senility.
Back to article page